With emerging biotechs playing a critical part in developing new drugs, Merck attempts to understand the interactions between parties when manufacturing monoclonal antibodies (mAbs).
Triangular
Over the last decade, emerging biotechnology companies have played an increasingly critical role in the development of new drugs. According to a recent IQVIA report, emerging biotechs, (defined as companies with less than $500 million in revenue) patented more than 60% of the 59 new drugs that launched in 2018 (up from 50% in 2010). Furthermore, these organisations account for more than 70% of the current assets in the late-stage pipeline (up from 61% in 2008).
Contract manufacturing organisations (CMOs) and contract development and manufacturing organisations (CDMOs), together with their partners in the emerging biotechnology sector, play an integral role to support the swift and cost-effective development of novel drugs as they can help reduce the need for large upfront capital expenditures to build infrastructure. (See Figure 1)